类似葡萄糖-1受体激活剂对勃起功能的影响:朋友还是敌人?
Dimitris Kounatidis1, Natalia G Vallianou2, Eleni Rebelos1,3,4
1Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece.
Biomolecules
|September 27, 2025
概括
勃起功能障碍 (ED) 是一种常见的糖尿病并发症. 本综述研究了类似葡萄糖类-1受体激动剂 (GLP-1RA) 和它们与2型糖尿病患者的ED复杂关系.
科学领域:
- 内分泌学 在内分泌学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
背景情况:
- 勃起功能障碍 (ED) 是糖尿病的一种普遍的微血管并发症,受年龄,疾病持续时间,血糖控制,胰岛素抵抗和雄激素缺乏的影响.
- 2型糖尿病 (T2D) 和肥胖通常涉及雄激素缺乏,加剧ED.
- 关于ED抗糖尿病疗法的现有研究产生了不一致的结果.
研究的目的:
- 审查当前关于葡萄糖类-1受体激动剂 (GLP-1RA) 对勃起功能影响的证据.
- 探索GLP-1RA在治疗糖尿病相关性ED时的潜在益处和风险.
- 识别知识上的差距,指导未来的研究方向.
主要方法:
- 现有实验和临床研究的叙述性审查.
- 关于GLP-1RA对勃起功能影响的综合数据.
- 对初步报告的分析表明了正面和负面的关联.
主要成果:
- 由于降糖,心血管和减肥的好处,GLP-1RA越来越多地用于T2D.
- 实验和临床数据表明GLP-1RA可能对勃起功能产生积极影响.
- 一些初步报告表明GLP-1RA使用与ED之间存在潜在的关联,需要进一步调查.
结论:
- GLP-1RA在勃起功能中的作用仍在研究中.
- 需要进一步的研究来澄清GLP-1RA和T2D中的ED之间的复杂关系.
- 了解这种关系对于优化糖尿病和ED管理至关重要.
相关概念视频
Glucagon-like Receptor Agonists
848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594
GPCRs Regulate Adenylyl Cylase Activity
7.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.3K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
560
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
560
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
525
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
525
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600


